title: Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
authors.forename: Shukui
authors.initials: S
authors.lastname: Qin
authors.affiliation: Science Editor, CCO, editor@thecco.net.
authors.forename: Shannon
authors.initials: S
authors.lastname: Zhang
mesh_terms: D001208:Asia / Q000453:epidemiology; D044466:Asian People; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology / Q000208:ethnology / Q000401:mortality / Q000556:secondary; D018572:Disease-Free Survival; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000208:ethnology / Q000401:mortality / Q000473:pathology; D058990:Molecular Targeted Therapy; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007093:Imidazoles; D007191:Indazoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib; D000077784:Axitinib